Fatty-acid binding protein 4 (FABP4), also termed adipocyte fatty-acid binding protein (A-FABP), or aP2, is a novel adipocyte-expressed factor which accounted for ~6% of total cellular proteins. Several animal experiments suggested that FABP-4 plays a key role in the link between obesity and various features of metabolic syndrome. Mice with targeted disruption of FABP-4 accompany FABP-5 almost completely protect against diet-induced obesity, insulin resistance, dyslipidemia, type 2 diabetes, and fatty liver disease. Studies in human found FABP-4 serum levels were significantly increased in overweight and obese subjects, which predicted the risk to develop a metabolic syndrome and type 2 diabetes. Additionally, serum FABP-4 levels were associated with nonalcoholic fatty liver disease, carotid atherosclerosis and coronary artery diseaseThis Human FABP4 ELISA kit is designed for quantification of Human FABP4 in serum, plasma, and adipocyte extracts or cell culture media samples.The lowest level of FABP4 that can be detected by this assay is 0.39 ng/ml.The antibodies used in this assay are specific to human FABP4 and do not cross-react with mouse and rat FABP4, and other cytokine or hormone molecules.
新西兰Symansis公司是新西兰一家发展抗体作为新药开发中细胞讯息传递研究工具的公司。
Symansis公司新推出Multi-Kinase ELISA Arrays试剂盒,采用特异的抗磷酸化激酶抗体和ELISA反应原理,使磷酸化激酶的检测变得简单。一次操作,可同时检测多个磷酸化激酶,避免了传统的Western blot方法需要分开操作及其一系列复杂繁琐的操作和等待。其酶抑制剂产品如下:
AKT AKt-I-1 SY AKT-I-1
AMPK A-769662 SY-A-769662
AUR (CDK) JNJ7706621 SY- JNJ7706621
Aurora VX-680 SY- VX-680
Bcl-2 ABT-737 SY- ABT-737
BCR-ABL Imatinib mesylate SY- Imatinib mesylate
BCR-ABL PD173955 SY-PD173955
CDK AT-7519 SY- AT-7519
CDK SNS-032 SY- SNS-032
EGFR Gefitinib SY- Gefitinib
EGFR Erlotinib SY- Erlotinib